Oak Ridge Investments LLC Has $1.34 Million Stock Holdings in Oyster Point Pharma, Inc. (NASDAQ:OYST)

Oak Ridge Investments LLC increased its position in shares of Oyster Point Pharma, Inc. (NASDAQ:OYST) by 2.1% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 73,361 shares of the company’s stock after acquiring an additional 1,496 shares during the period. Oak Ridge Investments LLC owned about 0.28% of Oyster Point Pharma worth $1,341,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Citigroup Inc. boosted its position in shares of Oyster Point Pharma by 89.3% during the 4th quarter. Citigroup Inc. now owns 1,723 shares of the company’s stock worth $32,000 after acquiring an additional 813 shares in the last quarter. Los Angeles Capital Management LLC boosted its position in shares of Oyster Point Pharma by 8.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 13,063 shares of the company’s stock worth $246,000 after acquiring an additional 1,010 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Oyster Point Pharma by 5.8% during the 4th quarter. Bank of New York Mellon Corp now owns 23,028 shares of the company’s stock worth $434,000 after acquiring an additional 1,272 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Oyster Point Pharma by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 70,011 shares of the company’s stock worth $1,318,000 after acquiring an additional 1,303 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Oyster Point Pharma by 10.5% during the 4th quarter. Alliancebernstein L.P. now owns 14,700 shares of the company’s stock worth $277,000 after acquiring an additional 1,400 shares in the last quarter. Institutional investors and hedge funds own 70.73% of the company’s stock.

Separately, Zacks Investment Research raised shares of Oyster Point Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, May 26th.

Shares of NASDAQ:OYST opened at $18.74 on Friday. The company has a market cap of $486.83 million, a P/E ratio of -6.51 and a beta of -0.33. The company has a 50 day moving average of $18.99. Oyster Point Pharma, Inc. has a one year low of $15.80 and a one year high of $33.60.

Oyster Point Pharma (NASDAQ:OYST) last issued its quarterly earnings data on Thursday, May 6th. The company reported ($0.73) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.91) by $0.18. On average, equities research analysts anticipate that Oyster Point Pharma, Inc. will post -3.69 EPS for the current year.

About Oyster Point Pharma

Oyster Point Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that has completed Phase III clinical trial for the treatment of signs and symptoms of dry eye disease.

See Also: How Does the Quiet Period Work?

Institutional Ownership by Quarter for Oyster Point Pharma (NASDAQ:OYST)

Receive News & Ratings for Oyster Point Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oyster Point Pharma and related companies with MarketBeat.com's FREE daily email newsletter.